Charles River Laboratories International, Inc. (NYSE:CRL) insider Davide Molho sold 5,982 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total transaction of $643,364.10. Following the completion of the transaction, the insider now directly owns 22,714 shares of the company’s stock, valued at $2,442,890.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Davide Molho also recently made the following trade(s):

  • On Thursday, June 22nd, Davide Molho sold 10,948 shares of Charles River Laboratories International stock. The shares were sold at an average price of $100.00, for a total transaction of $1,094,800.00.

Charles River Laboratories International, Inc. (NYSE CRL) traded up 0.95% during trading on Thursday, reaching $108.88. 139,270 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $101.50 and its 200-day moving average price is $94.39. The firm has a market cap of $5.18 billion, a price-to-earnings ratio of 28.69 and a beta of 0.99. Charles River Laboratories International, Inc. has a 12 month low of $67.20 and a 12 month high of $109.38.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. The firm had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.20 EPS. On average, equities research analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has initiated a share repurchase plan on Wednesday, May 10th that allows the company to repurchase $150.00 million in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/07/insider-selling-charles-river-laboratories-international-inc-crl-insider-sells-5982-shares-of-stock.html.

Several equities analysts recently weighed in on CRL shares. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Citigroup Inc. reissued a “neutral” rating and issued a $104.00 target price (up from $90.00) on shares of Charles River Laboratories International in a research note on Thursday, May 11th. Robert W. Baird reissued a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research note on Friday, September 1st. BidaskClub cut shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Barclays PLC reissued a “hold” rating and issued a $102.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $98.65.

Large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Charles River Laboratories International by 12.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 202 shares during the period. Riverhead Capital Management LLC grew its stake in Charles River Laboratories International by 14.7% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares during the period. Cambridge Advisors Inc. bought a new position in Charles River Laboratories International in the 2nd quarter valued at $202,000. Advisor Partners LLC bought a new position in Charles River Laboratories International in the 2nd quarter valued at $208,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in Charles River Laboratories International in the 2nd quarter valued at $217,000. Hedge funds and other institutional investors own 95.82% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.